TSO3 Engages Liolios Group to Lead New Strategic Investor Relations Program

TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, has engaged Liolios Group to lead a new strategic investor relations and financial communications program.

"The recent months have been highly transformative for TSO3, following the long-anticipated FDA 510(k) clearance of our flagship STERIZONE® VP4 low temperature sterilizer last December," says TSO3 president and CEO, Ric Rumble. "With our product's superior claims over the competition and strong initial sales channels in place, we have seen the creation of a rapidly expanding opportunity pipeline. We have received initial orders and are preparing to officially open our new distribution and customer support facility based in South Carolina in October. The company has clearly entered the commercialization stage of its development."

"Having reached this pivotal point in our growth trajectory, we believe our shareholders will benefit from an experienced team of financial communication professionals to help us navigate the capital markets and generate greater awareness of TSO3 in the investment community," continues Rumble. "Liolios Group brings a proven record of helping emerging growth companies like ours, enhance shareholder value by delivering the right message to the right audience and establishing high-quality, long-term relationships with influential members of the financial community."

Over the course of the next several weeks, Liolios Group will work closely with TSO3 management to develop and execute a comprehensive capital markets strategy. Activities will include messaging and corporate positioning, strategic advisory and introductions to analysts, investors and other key influencers across the financial community. Liolios Group will also schedule a number of road shows and financial conferences for management over the next several months.

The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for a cost effective and error-free sterilization process. TSO3's unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75 lb load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.

Source: TSO3